Enterprise Therapeutics secures £26M funding for cystic fibrosis treatment
Enterprise Therapeutics, a Brighton, UK-based biopharmaceutical company, has recently secured £26M in Series B follow-on funding. The funding round was led by Panakes Partners, with participation from existing investors Versant Ventures, Novartis Venture Fund, Forbion, Epidarex Capital, and IP Group. As a result of the investment, Dr Rob Woodman from Panakes joins Enterprise's Board of Directors. The primary goal of this funding is to accelerate the Phase 2a clinical trial of their lead program, ETD001, with the aim of providing clinical proof of concept for the treatment of cystic fibrosis.
Enterprise Therapeutics, under the leadership of CEO Dr John Ford, is dedicated to developing innovative therapies for respiratory disease.
Their lead program, ETD001, focuses on the ENaC ion channel in the airway epithelium to enhance mucus hydration and clearance. By targeting this channel, ETD001 aims to improve lung function and provide long-lasting effects. The upcoming clinical trial will specifically address cystic fibrosis patients who are ineligible for or not receiving CFTR modulators, assessing the impact on FEV1 lung function.
In addition to advancing their lead program, Enterprise Therapeutics plans to expand their clinical activities in Italy. This expansion involves establishing new clinical investigator sites and progressing their other preclinical programs that target mucus congestion. With this comprehensive approach, Enterprise Therapeutics aims to make significant strides in the treatment of respiratory diseases, ultimately enhancing the quality of life for patients.
They've invested in Enterprise Therapeutics
Get to know these Biotech investors
Click here for a full list of 7,526+ startup investors in the UK